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Innovations
Metabolix, Inc. and Tepha, Inc.
Bioplastics for Industry and Medical Devices
than could be done with natural terials for their own applications.
“Our purpose now is to commercial-strains.”
ize PHAs with strategic alliancesMIT filed the first patents on the
Traditionally, the plastics and spe-
cialty chemicals industries have
been led by familiar names like Dow,
with other companies and see thatMonsanto, and DuPont. But since concept that genetic engineering
they enter the marketplace,” says1992, a small company has been would play a crucial role in develop-
CEO Jim Barber, PhD, an organicmaking inroads into commercial pro- ing manufacturing technology for
chemist who has spent his career induction of environmentally friendly PHAs. MIT identified and patented
the specialty chemicals and materi-specialty polymers and chemicals—a the key genes and the use of the
als industries.market growing in consumer de- genes to make these PHA materials.
“We’re a 30-person company in amand and product options. Meta- Metabolix licensed the patents in
vast 300 billion pound plastics in-bolix, a 30-person operation head- 1993. “Since that time, we took the
dustry,” says Barber. The com-quartered in Cambridge, MA, is in basic MIT genes and developed a
pany’s plan is to achieve a marketthe business of making a versatile broadly enabling platform technol-
presence through partnerships suchfamily of biologically derived polyes- ogy to build our robust production
as the applications evaluation col-ters called polyhydroxyalkanoates strains,” says Peoples.
laboration with BASF announced inor PHAs. At the heart of the com- Lots of soil bacteria produce
July 2003.pany’s current production capabili- PHAs, which are essentially a re-
“We are now at the thresholdties are genetically modified bacte- served energy deposit within the
where PHAs are about to enter theria able to synthesize large amounts bacteria. “Instead of making starch,
marketplace, as they are now in pro-of PHA plastics from renewable, carbohydrate, oil, or fat, as most or-
totype in a number of different appli-nonpetrochemical sources.
cation areas,” says Barber. A keyFermented at MIT
milestone in the commercial suc-Metabolix owes its conception to “Instead of making starch, cess of PHA products has beenfounders Oliver Peoples, PhD, An-
Metabolix’s demonstration of PHAcarbohydrate, oil, or fat,thony Sinskey, ScD, and Simon Wil-
manufacturing at 60,000 liter, indus-liam, PhD, three MIT researchers as most organisms do, at
trial-scale fermentation.working in the fields of molecular some point these bacte- Metabolix is not alone in its questbiology and biochemistry. Begin-
to provide more environmentallyria evolved to make PHAning in the mid 1980s, the trio recog-
friendly plastics. DuPont has beennized the potential for metabolic polyesters as their re-
developing polymers from corn-gene technology strategies. “There tained energy source.” derived 1,3-propanediol, or PDO, withwas quite a bit of activity implement-
hopes of a 2004 commercial launch.–Oliver Peoples, PhD, Co-ing gene technology strategies with
Cargill Dow is working on Nature-the goal of improving bacterial founder and Chief Scien-
Works PLA, a biopolymer derivedstrains to produce therapeutic pro- tific Officer, Metabolix from lactic acid. Others in the arenateins,” recalls Peoples, now Chief
include Maxygen (through its Co-
Scientific Officer at Metabolix, “but
dexis subsidiary), BASF, Procter &
we were interested in biopolymers ganisms do, at some point these Gamble, Hercules, and many aca-
in particular.” bacteria evolved to make PHA poly- demic and research centers world-
The researchers then set to work esters as their retained energy wide. Metabolix is able to compete
using genetic engineering to control source,” says Peoples. He and his because of its strong intellectual
the pathways or chemical steps colleagues discovered a way to ge- property position surrounding its
leading toward improving biologi- netically alter the bacteria to pro- genetic engineering technology. “Our
cally based PHA production in bac- duce much larger quantities of the IP position prevents others from us-
teria. “If we could dictate what path- polymer. Metabolix’s bacteria today ing genetic engineering to boost
ways were followed, what molecules are essentially morbidly obese cells production and control composition
were made, and what molecules composed of nearly 85% PHA bio- and properties,” says Peoples.
were polymerized, we theorized we mass derived via fermentation of Applications
could then make any kind of polymer natural sugar and oils. Biology makes essentially 4–5 poly-
we wanted,” says Peoples. “The ba- Commercializing PHAs mer types including proteins, poly-
sic idea was to use genetic engi- Metabolix’s strength is in engi- saccharides, and nucleic acids. Al-
neering to produce polymers more neering bacterial strains to make most all of them interact with water,
reproducibly, cost effectively, and PHAs through fermentation. Other making them poor candidates for
barrier materials. PHAs are uniquewith a broader range of performance companies will then apply those ma-
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in that they are true high molecular with a high degree of control,” says “We plan on making a variety of
Peoples. “And it has brought us toweight polyesters and are very di- medical products ranging from rela-
a cost structure nearing $0.50/lbverse. Nearly 100 different PHA build- tively simple medical devices, such
that is very attractive for some mid-ing blocks can be engineered, but as sutures and meshes, to orthope-
level plastics markets,” adds Bar-only about 10–12 are relevant for dic devices to bioengineered heart
ber. But they both concede thatmaking functional polyesters. “The valves,” according to Ajay Ahuja,
plant science will be limited in thedifferent building blocks are made MD, Tepha’s Director of Business
flexibility of its output. Only a smallin the fermentation process with Development. They are primarily us-
number of PHA commodity-typethe bacterial strains,” says Barber. ing two strong and flexible PHA bio-
plastics will be made directly in“The key here is that we are putting materials, TephaFLEX and Teph-
plants. “But the cost will probably bethe pathways into the cell of the bac- ELAST, with TephELAST being the
less than petrochemical polymers,teria to convert sugar and other raw more flexible and elastic of the two.
and we cannot get that with fermen-materials into the building blocks we “Given the physical properties of
tation,” says Peoples. “We knowwant. Then, that same cell polymer- these PHAs—strong, flexible, exten-
that to carry the day we cannot justizes them into high molecular weight sible—the fact they are absorbable
rely on biodegradability and sus-polymers very efficiently.” By chang- and tissue friendly, and that we ex-
tainability,” says Barber. “It’s a greating the pathways, the type of build- pect to be able to control the rate of
tie breaker, but we know our prod-ing block created and then assem- absorption, we hope to fit any medi-
ucts have to be economically com-bled is altered. cal need we investigate,” adds Ahuja.
petitive to enjoy widespread use.”“With several of these building With its TephaFLEX product,
Realizing this, Metabolix aims toblocks, we can achieve a wide range Tepha is also working on more flexi-
produce the PHAs in plants at a costof material properties, from hard and ble polymer-based coronary stents.
below $0.30/lb. “That means we willrigid to elastomeric and highly flexi- They are also working on a drug de-
be economically competitive withble,” says Peoples. They achieve livery technology loading drug into
polyethylene and polypropylene,”these different properties by com- polymer-based stents similar to the
says Barber. “In other words, if webining different ratios of those build- drug-eluting stents introduced com-
get this technology up to scale weing blocks. The company is currently mercially this year. Regenerative medi-
will have a disruptive technologyfocused on three prime application cine in the form of tissue engineering
that will affect the whole thermo-
areas. These include injection-molded is a key long-term potential opportu-
plastics industry.”
biodegradable materials, for which nity for the company. Specific appli-
Plants do not naturally make
the company received a grant from cations include a replacement heartPHAs, but Metabolix has proven
the Department of Defense, paper valve and a cell-seeded vascularplants can grow them by genetically
coatings that allow paper to be recy- patch, both developed in collabora-engineering the same basic genes
cled or degraded, and flushable fi- tion with Children’s Hospital in Bos-described in the initial MIT patents.
bers for nonwoven materials such as ton using TephaFLEX. In 2002, TephaThe company is using native switch-
those in personal hygiene products received a $3 million grant from thegrass plants, a perennial nonfood
and wipes. Other areas of interest National Institute of Standards andcrop requiring little fertilizer or pesti-
include adhesive applications and Technology’s Advanced Technologycide. “Our challenge now is to work
renewable packaging products. Program for its tissue engineeringon optimizing that system to make
Growing Plastics biopolymer scaffold program.significant levels of polymer and
In 2001, Metabolix received a $7.4 also healthy plants,” says Peoples. Chemistry & Biology invites yourmillion grant from the Department Commercial applications are years comments on this topic. Pleaseof Energy for development of PHA away, although the effort got a boost write to the editors at chembiol@production directly in plants. This in September 2003 with an addi- cell.com.follows the creation of a modest pro- tional award from the USDA.
gram to produce PHA in plants that Medical Devices Alice McCarthy is a freelance science
began in 1998. “The plant program writer based in Gloucester, MA (alice@In the late 1990s, Metabolix cofoun-
is a significant portion of our R & D alicemccarthy.com).der Simon Williams began to foresee
effort and is going to be the ultimate medical applications for the com-
answer to sustainable manufacture pany’s polymer technology. He and
of polymers,” according to Peoples. others involved with Metabolix quickly
“And we know we will be able to realized that the issues involved in
produce these PHAs in plants, re- a highly regulated niche market such
cover the polymers, and use the as medical devices differ largely
plant residue for electric power gen- from those focused on large com-
eration.” The hoped-for net impact mercial-scale applications, where
will be that the polymer production cost and scale are significant con-
will produce excess energy and fix cerns. Thus, in 1998 Tepha, Inc. was
significant amounts of environmen- incorporated and spun off from Met-
tal CO2. abolix with Williams as President
“The fermentation system is ex- and CEO. The 6-person company is
tremely flexible, so you can make a located blocks from its sister com-
pany in Cambridge.wide range of different materials
